About Unconventional myosin-VIIb
Unconventional myosin-VIIb (MYO7B) is a protein
from Homo sapiens identified by UniProt accession
Q6PIF6, 2116 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Unconventional myosin-VIIb |
|---|
| UniProt accession | Q6PIF6 |
|---|
| Gene | MYO7B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2116 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (34)
Diseases linked to this target (Open Targets).
- protein C measurement · score 0.30
- neurodegenerative disease · score 0.30
- Barrett's esophagus · score 0.08
- esophageal adenocarcinoma · score 0.04
- hyperinsulinism due to INSR deficiency · score 0.04
- leukocyte count · score 0.04
- pseudohypoaldosteronism type 2B · score 0.04
- pseudohypoaldosteronism type 2D · score 0.04
- isolated hyperchlorhidrosis · score 0.04
- exercise-induced hyperinsulinism · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6PIF6-F1 | alphafold | PREDICTED | 77.83 | — |
Amino-acid sequence (2116 residues)
MSGFRLGDHV WLEPPSTHKT GVAIGGIIKE AKPGKVLVED DEGKEHWIRA EDFGVLSPMH PNSVQGVDDM IRLGDLNEAG MVHNLLIRYQ QHKIYTYTGS ILVAVNPFQV LPLYTLEQVQ LYYSRHMGEL PPHVFAIANN CYFSMKRNKR DQCCIISGES GAGKTETTKL ILQFLATISG QHSWIEQQVL EANPILEAFG NAKTIRNDNS SRFGKYIDIY FNPSGVIEGA RIEQFLLEKS RVCRQAPEER NYHIFYCMLM GVSAEDKQLL SLGTPSEYHY LTMGNCTSCE GLNDAKDYAH IRSAMKILQF SDSESWDVIK LLAAILHLGN VGFMASVFEN LDASDVMETP AFPTVMKLLE VQHQELRDCL IKHTILIRGE FVTRSLNIAQ AADRRDAFVK GIYGHLFLWI VKKINAAIFT PPAQDPKNVR RAIGLLDIFG FENFENNSFE QLCINFANEH LQQFFVQHVF TMEQEEYRSE NISWDYIHYT DNRPTLDLLA LKPMSIISLL DEESRFPQGT DLTMLQKLNS VHANNKAFLQ PKNIHDARFG IAHFAGEVYY QAEGFLEKNR DVLSTDILTL VYSSKNKFLR EIFNLELAET KLGHGTIRQA KAGNHLFKSA DSNKRPSTLG SQFKQSLDQL MKILTNCQPY FIRCIKPNEY KKPLLFDREL CLRQLRYSGM METVHIRKSG FPIRYTFEEF SQRFGVLLPN AMRMQLQGKL RQMTLGITDV WLRTDKDWKA GKTKIFLRDH QDTLLEVQRS QVLDRAALSI QKVLRGYRYR KEFLRQRRAA VTLQAWWRGY CNRRNFKLIL VGFERLQAIA RSQPLARQYQ AMRQRTVQLQ ALCRGYLVRQ QVQAKRRAVV VIQAHARGMA ARRNFQQRKA NAPLVIPAEG QKSQGALPAK KRRSIYDTVT DTEMVEKVFG FLPAMIGGQE GQASPHFEDL ESKTQKLLEV DLDTVPMAEE PEEDVDGLAE YTFPKFAVTY FQKSASHTHI RRPLRYPLLY HEDDTDCLAA LVIWNVILRF MGDLPEPVLY ARSSQQGSSV MRQIHDTLGR EHGAQVPQHS RSAQVASQLN IGEEALEPDG LGADRPMSNL EKVHFIVGYA ILRPSLRDEI YCQICKQLSE NFKTSSLARG WILLSLCLGC FPPSERFMKY LLNFIGQGPA TYGPFCAERL RRTYANGVRA EPPTWLELQA VKSKKHIPIQ VILATGESLT VPVDSASTSR EMCMHIAHKQ GLSDHLGFSL QVAVYDKFWS LGSGRDHMMD AIARCEQMAQ ERGESQRQSP WRIYFRKEFF TPWHDSREDP VSTELIYRQV LRGVWSGEYS FEKEEELVEL LARHCYVQLG ASAESKAVQE LLPSCIPHKL YRTKPPDRWA SLVTAACAKA PYTQKQVTPL AVREQVVDAA RLQWPLLFSR LFEVITLSGP RLPKTQLILA VNWKGLCFLD QQEKMLLELS FPEVMGLATN REAQGGQRLL LSTMHEEYEF VSPSSVAIAE LVALFLEGLK ERSIFAMALQ DRKATDDTTL LAFKKGDLLV LTKKQGLLAS ENWTLGQNDR TGKTGLVPMA CLYTIPTVTK PSAQLLSLLA MSPEKRKLAA QEGQFTEPRP EEPPKEKLHT LEEFSYEFFR APEKDMVSMA VLPLARARGH LWAYSCEPLR QPLLKRVHAN VDLWDIACQI FVAILRYMGD YPSRQAWPTL ELTDQIFTLA LQHPALQDEV YCQILKQLTH NSNRHSEERG WQLLWLCTGL FPPSKGLLPH AQKFIDTRRG KLLAPDCSRR IQKVLRTGPR KQPPHQVEVE AAEQNVSRIC HKIYFPNDTS EMLEVVANTR VRDVCDSIAT RLQLASWEGC SLFIKISDKV ISQKEGDFFF DSLREVSDWV KKNKPQKEGA PVTLPYQVYF MRKLWLNISP GKDVNADTIL HYHQELPKYL RGFHKCSRED AIHLAGLIYK AQFNNDRSQL ASVPKILREL VPENLTRLMS SEEWKKSILL AYDKHKDKTV EEAKVAFLKW ICRWPTFGSA FFEVKQTSEP SYPDVILIAI NRHGVLLIHP KTKDLLTTYP FTKISSWSSG STYFHMALGS LGRGSRLLCE TSLGYKMDDL LTSYVQQLLS AMNKQRGSKA PALAST
Explore Unconventional myosin-VIIb with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets